|Patients and clinical setting||Comparison||Number of trials (n)||Outcome||Weighted mean difference (95% CI)|
|*ED = emergency department; ICU = intensive care unit; MDI = metered dose inhaler; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second. CI defined in glossary.|
|†All but 1 of the trials were clinical laboratory trials.|
|Adults and children in the ED or ICU||Nebuliser v MDI + spacer/holding chamber for short acting β2 agonists||9 (510)||FEV1||0.13 (−0.04 to 0.31)|
|11 (708)||Symptom scores||0.01 (−0.32 to 0.34)|
|Adults in the ED/ICU||Continuous v intermittent nebulisation for short acting β2 agonists||3 (137)||FEV1||0.07 (−0.63 to 0.77)|
|Adult and child inpatients||Nebuliser v MDI + spacer/holding chamber for short acting β2 agonists||3 (102)||FEV1||0.05 (−0.34 to 0.44)|
|2 (91)||Symptom scores||−0.04 (−0.46 to 0.37)|
|Adult outpatients||DPI v MDI + spacer/holding chamber for corticosteroids†||2 (44)||FEV1||0.09 (−0.33 to 0.51)|
|4 (257)||Symptom scores||0.08 (−0.47 to 0.62)|
Review: various devices for delivery of aerosol treatment can be equally efficacious
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>
EBN Online Journal Club
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.